+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Sorafenib in metastatic thyroid cancer: a systematic review

Sorafenib in metastatic thyroid cancer: a systematic review

Oncologist 19(3): 251-258

Sorafenib was recently approved by the U.S. Food and Drug Administration for radioiodine-resistant metastatic differentiated thyroid cancer (DTC). In addition, two drugs (vandetanib and cabozantinib) have received U.S. Food and Drug Administration approval for use in medullary thyroid cancer (MTC). Several published phase II trials have investigated the efficacy of sorafenib in thyroid cancers, but to date, results from those studies have not been compared. A systematic review of the literature was performed to assess response rate, median progression-free survival, and adverse events associated with sorafenib therapy for metastatic thyroid cancers. This review included seven trials involving 219 patients: 159 with DTC (papillary, follicular, and poorly differentiated), 52 with MTC, and 8 with anaplastic thyroid cancer. No study reported complete responses to treatment. Overall partial response, stable disease, and progressive disease rates were 21%, 60%, and 20%, respectively. The median progression-free survival was 18 months for patients with all subtypes of thyroid cancer. Drug was discontinued in 16% of patients because of toxicities or intolerance, and the dose was reduced in a further 56%. Side effects with an incidence ≥ 50% were hand-foot syndrome (74%), diarrhea (70%), skin rash (67%), fatigue (61%), and weight loss (57%). Deaths not related to progressive disease occurred in nearly 4% of patients. Treatment with sorafenib in patients with progressive DTC and MTC is a promising strategy, but the adverse event rate is high, leading to a high rate of dose reduction or discontinuation. Consequently, sorafenib use in patients with metastatic thyroid cancer requires careful selection of patients and careful management of side effects.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 055854262

Download citation: RISBibTeXText

PMID: 24563075

DOI: 10.1634/theoncologist.2013-0362

Related references

Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents. Critical Reviews in Oncology/Hematology 99: 324-331, 2016

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis. Oncotarget 8(12): 20441-20451, 2017

Sorafenib in metastatic thyroid cancer. Endocrine-Related Cancer 19(2): 209-216, 2012

Phase II trial of sorafenib in metastatic thyroid cancer. Journal of Clinical Oncology 27(10): 1675-1684, 2009

Sorafenib makes headway on metastatic thyroid cancer. Cancer Discovery 3(7): Of2-Of2, 2014

Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma. Targeted Oncology 10(1): 171-178, 2015

Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer. Oncotargets and Therapy 7: 1291-1299, 2014

Updated Data for Sorafenib Reported for Metastatic Differentiated Thyroid Cancer. Oncology Times 36: 2-4, 2014

Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer. Yearbook of Endocrinology 2011: 123-124, 2011

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. Journal of Clinical Oncology 28(14): 2323-2330, 2010

Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer. Endocrine 42(3): 756-757, 2012

Thyroid dysfunction in patients (pts) with metastatic renal cell cancer (RCC) treated with sorafenib. Journal of Clinical Oncology 26(15_Suppl): 16145-16145, 2016

Pattern of spread to the lateral neck in metastatic well-differentiated thyroid cancer: a systematic review and meta-analysis. Thyroid 23(5): 583-592, 2013

Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review. Clinical Genitourinary Cancer 14(4): 277-283, 2016

Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. Journal of Clinical Oncology 26(15_Suppl): 5127-5127, 2016